Skip to content
Baret News – Lifestyle
Author:
Moderna, Inc.
Moderna to Present at Upcoming Conferences in September 2026
September 1, 2026
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
August 28, 2026
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
August 27, 2026
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
August 27, 2026
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
August 5, 2026
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna’s Investigational Vaccine Against Bundibugyo Ebolavirus
August 4, 2026
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
July 31, 2026
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
July 16, 2026
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
July 9, 2026
Moderna Appoints Michael McDonnell to Board of Directors
July 8, 2026
←
Previous Page
1
2
3
Next Page
→